---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021758"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:04:59.881195+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q2 2022 net loss $14.6M; cash $152.4M; OV329 IND on track for H2 2022

## Summary
- Net loss $14.6M ($0.21 per share) vs $15.8M loss ($0.23) in Q2 2021.
- Cash, equivalents & marketable securities $152.4M, expected to fund pipeline into 2025.
- R&D expenses $6.0M (down from $7.7M) due to discontinuation of OV101 study and Takeda termination.
- OV329 IND submission and Phase 1 start planned for H2 2022; preclinical data shown at epilepsy meetings.
- KCC2 activator IND expected in 2024; Takeda reiterates soticlestat regulatory filing in FY2024.

## SEC filing metadata
- accession: 0001628280-22-021758
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828022021758/0001628280-22-021758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828022021758/ovid-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021758
- JSON: https://secwatch.observer/filing/0001628280-22-021758.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.